NZ572893A - Myxoma virus mutants for cancer treatment - Google Patents
Myxoma virus mutants for cancer treatmentInfo
- Publication number
- NZ572893A NZ572893A NZ572893A NZ57289307A NZ572893A NZ 572893 A NZ572893 A NZ 572893A NZ 572893 A NZ572893 A NZ 572893A NZ 57289307 A NZ57289307 A NZ 57289307A NZ 572893 A NZ572893 A NZ 572893A
- Authority
- NZ
- New Zealand
- Prior art keywords
- myxoma virus
- cell
- activity
- group
- cancer
- Prior art date
Links
- 241000700562 Myxoma virus Species 0.000 title claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 32
- 201000011510 cancer Diseases 0.000 title claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 102220361483 c.31A>T Human genes 0.000 claims abstract description 11
- 230000002950 deficient Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 40
- 206010018338 Glioma Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 208000032612 Glial tumor Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 12
- 230000014509 gene expression Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000010076 replication Effects 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 101150061325 mv gene Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80364006P | 2006-06-01 | 2006-06-01 | |
| PCT/US2007/070219 WO2007143548A2 (en) | 2006-06-01 | 2007-06-01 | Myxoma virus mutants for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ572893A true NZ572893A (en) | 2011-06-30 |
Family
ID=38802246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ572893A NZ572893A (en) | 2006-06-01 | 2007-06-01 | Myxoma virus mutants for cancer treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8512713B2 (enExample) |
| EP (3) | EP3254694A1 (enExample) |
| JP (4) | JP2009538935A (enExample) |
| KR (1) | KR20090014364A (enExample) |
| CN (1) | CN101460194B (enExample) |
| AU (1) | AU2007256754B2 (enExample) |
| CA (2) | CA2652228C (enExample) |
| IL (1) | IL195297A (enExample) |
| MX (1) | MX2008015265A (enExample) |
| NZ (1) | NZ572893A (enExample) |
| WO (1) | WO2007143548A2 (enExample) |
| ZA (1) | ZA200809769B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007256754B2 (en) | 2006-06-01 | 2012-11-29 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
| FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
| US12128099B2 (en) | 2018-05-25 | 2024-10-29 | Bioventures, Llc | Myxoma virus compositions and methods of use |
| EP3846829A4 (en) * | 2018-09-05 | 2022-09-14 | Arizona Board of Regents on behalf of Arizona State University | ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER |
| WO2020106880A1 (en) | 2018-11-20 | 2020-05-28 | Bioventures, Llc | Cells for the production of viruses and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| EP1200595A2 (en) | 1999-07-12 | 2002-05-02 | Viron Therapeutics, Inc. | Myxoma virus genes for immune modulation |
| WO2001087324A1 (en) | 2000-05-17 | 2001-11-22 | Viron Therapeutics, Inc. | Compositions and methods for promoting immunosuppression |
| DE60209345T2 (de) * | 2001-03-08 | 2006-08-03 | Akzo Nobel N.V. | Leporipox-basierende vektorvakzine |
| US7582614B2 (en) * | 2003-03-07 | 2009-09-01 | Robarts Research Institute | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection |
| NZ550430A (en) | 2004-04-27 | 2009-06-26 | Wellstat Biologics Corp | Cancer treatment using viruses and camptothecins |
| DK2388315T3 (da) * | 2005-03-07 | 2014-08-25 | Univ Western Ontario | Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling |
| WO2007143545A2 (en) | 2006-06-01 | 2007-12-13 | Robarts Research Institute | Tnf signaling in myxoma virus treatments |
| AU2007256754B2 (en) | 2006-06-01 | 2012-11-29 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
| WO2007147118A1 (en) | 2006-06-16 | 2007-12-21 | Robarts Research Institute | Infection of cells with myxoma virus requires akt activation |
-
2007
- 2007-06-01 AU AU2007256754A patent/AU2007256754B2/en not_active Ceased
- 2007-06-01 CA CA2652228A patent/CA2652228C/en not_active Expired - Fee Related
- 2007-06-01 EP EP17182211.7A patent/EP3254694A1/en not_active Withdrawn
- 2007-06-01 CN CN2007800202887A patent/CN101460194B/zh not_active Expired - Fee Related
- 2007-06-01 EP EP07798014A patent/EP2021023A4/en not_active Withdrawn
- 2007-06-01 EP EP11184754.7A patent/EP2457584B1/en not_active Not-in-force
- 2007-06-01 KR KR1020087029274A patent/KR20090014364A/ko not_active Ceased
- 2007-06-01 JP JP2009513472A patent/JP2009538935A/ja not_active Withdrawn
- 2007-06-01 NZ NZ572893A patent/NZ572893A/en not_active IP Right Cessation
- 2007-06-01 MX MX2008015265A patent/MX2008015265A/es active IP Right Grant
- 2007-06-01 WO PCT/US2007/070219 patent/WO2007143548A2/en not_active Ceased
- 2007-06-01 CA CA2951453A patent/CA2951453A1/en not_active Abandoned
- 2007-06-01 US US12/301,961 patent/US8512713B2/en not_active Expired - Fee Related
-
2008
- 2008-11-13 ZA ZA200809769A patent/ZA200809769B/xx unknown
- 2008-11-13 IL IL195297A patent/IL195297A/en active IP Right Grant
-
2013
- 2013-03-01 JP JP2013040387A patent/JP5665899B2/ja not_active Expired - Fee Related
- 2013-08-19 US US13/969,853 patent/US20130336930A1/en not_active Abandoned
-
2014
- 2014-12-09 JP JP2014248831A patent/JP2015044878A/ja active Pending
-
2016
- 2016-01-21 US US15/002,971 patent/US9980994B2/en active Active
- 2016-10-06 JP JP2016197808A patent/JP2017008105A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9980994B2 (en) | 2018-05-29 |
| JP2013100370A (ja) | 2013-05-23 |
| EP2021023A2 (en) | 2009-02-11 |
| IL195297A (en) | 2015-04-30 |
| KR20090014364A (ko) | 2009-02-10 |
| MX2008015265A (es) | 2008-12-12 |
| CN101460194A (zh) | 2009-06-17 |
| US20110158945A1 (en) | 2011-06-30 |
| AU2007256754A1 (en) | 2007-12-13 |
| EP2457584A1 (en) | 2012-05-30 |
| US8512713B2 (en) | 2013-08-20 |
| JP2017008105A (ja) | 2017-01-12 |
| CA2951453A1 (en) | 2007-12-13 |
| EP2457584B1 (en) | 2017-08-09 |
| US20130336930A1 (en) | 2013-12-19 |
| AU2007256754B2 (en) | 2012-11-29 |
| CN101460194B (zh) | 2013-08-14 |
| US20160136212A1 (en) | 2016-05-19 |
| JP2009538935A (ja) | 2009-11-12 |
| ZA200809769B (en) | 2009-07-29 |
| EP3254694A1 (en) | 2017-12-13 |
| JP5665899B2 (ja) | 2015-02-04 |
| EP2021023A4 (en) | 2010-08-11 |
| WO2007143548A2 (en) | 2007-12-13 |
| CA2652228C (en) | 2017-07-11 |
| CA2652228A1 (en) | 2007-12-13 |
| IL195297A0 (en) | 2009-08-03 |
| WO2007143548A3 (en) | 2008-09-25 |
| JP2015044878A (ja) | 2015-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hirsch et al. | Macrophages and age-dependent resistance to herpes simplex virus in mice | |
| US9980994B2 (en) | Myxoma virus mutants for cancer treatment | |
| Markert et al. | Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir | |
| Sampath et al. | Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects | |
| WO2008140621A2 (en) | Transgenic oncolytic viruses and uses thereof | |
| US20220339220A1 (en) | Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancers | |
| US20130171106A1 (en) | Use of a combination of myxoma virus and rapamycin for therapeutic treatment | |
| AU2980000A (en) | Treatment of tumors with genetically engineered herpes virus | |
| Gridley et al. | Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. | |
| Wodarz | Computational approaches to study oncolytic virus therapy: insights and challenges | |
| HK1247113A1 (en) | Myxoma virus mutants for cancer treatment | |
| HK1170951A (en) | Myxoma virus mutants for cancer treatment | |
| US8613915B2 (en) | Attenuated strain of myxoma virus for use as an oncolytic drug | |
| Ding et al. | Evaluation of tumor specificity and immunity of thymidine kinase-deleted vaccinia virus guang9 strain | |
| Lin et al. | Antagonistic action of retinoic acid against teleocidin and 12-O-tetradecanoyl-phorbol-13-acetate on activation of Epstein-Barr virus genomes | |
| HK40011176A (en) | Therapeutic agent and application thereof in drugs for treating tumors and/or cancer | |
| HK40011177A (en) | Therapeutic agent comprising oncolytic viruses and nk cells and application thereof in drugs for treating tumors and/or cancer | |
| HK1163175B (en) | Use of a myxoma virus that does not express functional m135r for therapeutic treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 JUN 2017 BY CPA GLOBAL Effective date: 20140417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2018 BY CPA GLOBAL Effective date: 20170421 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2019 BY MURGITROYD + CO Effective date: 20180601 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2020 BY MARTIN HUNTER Effective date: 20190531 |
|
| LAPS | Patent lapsed |